Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7058 in advanced solid tumors with KRAS G12C mutation
NCT06383871Phase 1Recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-7058 in solid tumor (advanced stage), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 10 months, Maximum Tolerated Dose at 10 months and 2 more. Started Jun 2024; status: recruiting.
02
Drugs
HRS-7058
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06383871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383871.